Skip to main content
Top
Published in:

Open Access 01-12-2025 | Obesity | Systematic Review

Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta analysis

Authors: Shengxuan Zhang, Bixuan Sun, Lei Sun, Shijian Zou, Qilan Chen

Published in: BMC Endocrine Disorders | Issue 1/2025

Login to get access

Abstract

Objective

Dietary patterns play a vital role in the health management of individuals with metabolic syndrome. Many recent studies have shown that intermittent fasting (IF) has better effects, such as improving obesity. Nevertheless, it warrants further investigation to determine which approach is more effective in comparison to continuous energy restriction (CR), particularly when total calorie intake shows minimal variation. Consequently, it is crucial to evaluate the degree of enhancement of the two dietary patterns concerning different aspects of metabolic syndrome. This study presents a meta-analysis of randomized controlled trials (RCTs) aimed at comparing the impacts of IF and CR on obesity and glucolipid metabolism in individuals diagnosed with metabolic syndrome.

Methods

In August 2024, a thorough examination of English-language literature was performed across the PubMed, Medline, Embase, and Cochrane Library databases. The meta-analyses was performed according to the established guidelines and reported the results. Weight change, Body Mass Index (BMI) change, and triglyceride (TG) level change were designated as key assessment indicators, while blood pressure, blood glucose, hip circumference, and waist circumference served as supplementary indicators for comparative analysis.

Result

A total of nine studies involving 626 patients were analyzed, focusing on the influence of dietary patterns on obesity, cholesterol levels, and insulin resistance among individuals diagnosed with metabolic syndrome. Both dietary patterns were beneficial for patients with metabolic syndrome. However, IF was better than CRin terms of improvement in obesity over the trial period (mean -1.77, 95% CI [-3.06, -0.48]), and it was more conducive to a reduction in TG levels, which was beneficial in terms of improving insulin resistance (mean -10.16, 95% CI [-18.88, -1.45]).

Conclusion

Given its notable advantages for obesity, lipids, and insulin resistance, along with improved patient adherence, IF may be regarded as a more effective dietary approach for individuals with metabolic syndrome. Nonetheless, the long-term effectiveness still necessitates additional validation.

Prospero registration

CRD42024587335.
Appendix
This content is only visible if you are logged in and have the appropriate permissions.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta analysis
Authors
Shengxuan Zhang
Bixuan Sun
Lei Sun
Shijian Zou
Qilan Chen
Publication date
01-12-2025
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2025
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-025-01952-x

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Watch the full video

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by: Abbott Diabetes Care

Log in / Register to watch the full video

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025: the 85th Scientific Sessions

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s annual meeting.

Read more